Clinical Trial Update: Lonafarnib and Temozolomide in Treating Patients with Glioblastoma Multiforme That is Recurrent or Did Not Respond to Previous Treatment with Temozolomide [Phase 1]

View source ↗

Summary

Phase 1 trial update evaluating lonafarnib in combination with temozolomide for recurrent glioblastoma multiforme and related gliomas.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma
• Glioblastoma Multiforme
• Gliosarcoma

Drugs mentioned

• Lonafarnib (lonafarnib)
• Temozolomide (Temozolomide)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Malignant Supratentorial Neoplasm, Recurrent Glioblastoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING